Detected ·
Xeltis
€20.5M—
Xeltis, a Dutch medtech company developing living-tissue vascular implants for hemodialysis patients, secured an additional €20.5M led by Horizon 3 Healthcare, with participation from EIC, Invest-NL, Vi Partners, EQT Life Sciences, DaVita Kidney Care, and existing shareholders. The funding will support the US pivotal trial of its CE-marked aXess implantable blood vessel, FDA submission, and European rollout.
- Website
- www.xeltis.com
- linkedin.com/company/xeltis
- Amount
- €20 500 000 EUR
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-09 16:01:45 UTC
- Signal ID
- 0456badc-5574-48b5-b179-0b88deb9106c
As the API returns it
{
"id": "0456badc-5574-48b5-b179-0b88deb9106c",
"created_at": "2026-08-09T16:01:45.159939Z",
"company_name": "Xeltis",
"company_website_url": "www.xeltis.com",
"company_linkedin_url": "https://www.linkedin.com/company/xeltis",
"event_type": "funding",
"funding_amount": 20500000,
"funding_currency": "EUR",
"funding_stage": null,
"message": "*Xeltis, a Dutch medtech company developing living-tissue vascular implants for hemodialysis patients, secured an additional €20.5M led by Horizon 3 Healthcare, with participation from EIC, Invest-NL, Vi Partners, EQT Life Sciences, DaVita Kidney Care, and existing shareholders. The funding will support the US pivotal trial of its CE-marked aXess implantable blood vessel, FDA submission, and European rollout.*"
}